reports
- ABGSC Healthcare Research
- Philip Ekengren
- Sten Gustafsson
- ABGSC Healthcare Research
- Sten Gustafsson
- ABGSC Small Cap Research
- Karl Bokvist
- Nikola Kalanoski
- Simon Jönsson
CTT CTT SYSTEMS AB
PREV B PREVAS B
CATE CATENA AB
GENI GENERIC SWEDEN AB PUBL
DUST DUSTIN GROUP AB
EKTA B ELEKTA AB CLASS B
STEF B STENDOERREN FASTIGHETER AB CLASS B
BONEX BONESUPPORT HOLDING AB
HMS HMS NETWORKS AB
MIPS MIPS AB
BOOZT BOOZT AB
A2DRL9 SDIPTECH AB B
FRACTL FRACTAL GAMING GROUP AB
RUG RUGVISTA GROUP AB
PACT PROACT IT GROUP
SFAB SOLID FORSAKRINGSAKTIEBOLAG
NOLA B NOLATO AB
HEM HEMNET GROUP AB (PUBL)
SLP B SWEDISH LOGISTIC PROPERTY AB
ITECH I-TECH AB
VESTUM VESTUM AB
ACAST-SE ACAST
SECT.B-SE SECTRA
GREEN GREEN LANDSCAPING GROUP AB (PUBL)
- ABGSC Healthcare Research
- Sten Gustafsson
- ABGSC Healthcare Research
- Sten Gustafsson
Arjo AB: 1 director
A director at Arjo AB bought 100,000 shares at 33.660SEK and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
- ABGSC Healthcare Research
- Sten Gustafsson
- ABGSC Healthcare Research
- Philip Ekengren
- Sten Gustafsson
- ABGSC Healthcare Research
- Philip Ekengren
- Sten Gustafsson
- ABGSC Healthcare Research
- Philip Ekengren
- Sten Gustafsson
- ABGSC Healthcare Research
- Sten Gustafsson
- ABGSC Healthcare Research
- Sten Gustafsson
- ABGSC Healthcare Research
- Philip Ekengren
- Sten Gustafsson
- ABGSC Healthcare Research
- Philip Ekengren
- Sten Gustafsson
- ABGSC Healthcare Research
- Philip Ekengren
- Sten Gustafsson
- Maria Vara
BONESUPPORT: 2025 Trim; Spine optionality kicks in
Following Q2 earnings, we revisited our expectations across all business segments, leading to a 9% 2025E sales cut, majorly driven by FX headwinds on US sales, while country-specific policies in EUROW led to softer-than-expected H1 growth. Our long-term thesis remains unchanged, and we see improvin
- ABGSC Healthcare Research
- Philip Ekengren
- Sten Gustafsson
- ABGSC Healthcare Research
- Sten Gustafsson
- Maria Vara
BONESUPPORT: Q2 US momentum in line; softer EU and FX weigh on EBIT
BONESUPPORT reported Q2 2025 net sales of SEK 284.4m, slightly below CSS SEK 291m (Stifel est. SEK 299m), with the deviation primarily due to a softer-than-expected European performance. Growth was led by the US, which grew 36% YoY reported (49% CER), though it fell -2%, and -4% vs CSS and our expe
- ABGSC Healthcare Research
- Sten Gustafsson
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.